Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $730.8M fell 1.9% year over year, in line with the -2.2% change in trailing-twelve-month revenue. Sequentially, it rose 65.0% from the prior quarter. Over 3 fiscal years it compounded at +33.1% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 16 analysts of $1.87B (-15.1%) for the fiscal year ending Dec 2026, a slowdown from the +15.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $730.8M+65.0% QoQ
- Last fiscal yearDec 2025
- $2.2B+15.6% YoY
- LTMMar 2026
- $2.18B-2.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.9% | -40.0% | -38.2 pp |
| 1 year | +15.6% | -15.1% | -30.7 pp |
| 3-year CAGR | +33.1% | -14.9% | -48.0 pp |
| 5-year CAGR | -12.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 2.2B USD
- Year-over-year change
- +15.6%
- 4-year CAGR
- +33.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.2B | +15.6% |
| FY2024 | 2024-12-31 | 1.9B | +53.0% |
| FY2023 | 2023-12-31 | 1.24B | +33.3% |
| FY2022 | 2022-12-31 | 933.01M | +32.9% |
| FY2021 | 2021-12-31 | 701.89M | — |
Revenue vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's LTM Mar 2026 revenue of $2.18B is the 2nd highest of the 11 companies compared; the peer median is $33.05M.
- Its year-over-year change of -2.2% is the 4th highest of 7, against a peer median of -16.2%.
- Over three fiscal years its annual growth of +33.1% compares with a peer median of +35.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $4.8B | +95.1% | +53.0% | |
| LTM Mar 2026 | $2.18B | -2.2% | +33.1% | |
| LTM Jun 2026 | $1.01B | -42.8% | +35.3% | |
| LTM Sep 2026 | $959.76M | -0.7% | +17.1% | |
| LTM Mar 2026 | $71.8M | -31.6% | +127.1% | |
| LTM Mar 2026 | $66.09M | +45.0% | +9.1% | |
| LTM Jun 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding SRPT) | $33.05M | -16.2% | +35.3% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 701.89M | 933.01M | 1.24B | 1.9B | 2.2B |
| Cost of Revenue | 97.05M | 139.99M | 150.34M | 319.1M | 881.5M |
| Gross Profit | 604.84M | 793.02M | 1.09B | 1.58B | 1.32B |
| Gross Margin | 86.2% | 85.0% | 87.9% | 83.2% | 59.9% |
| Research & Development | 771.18M | 877.09M | 877.39M | 804.52M | 1.52B |
| Selling, General & Admin | 282.66M | 451.42M | 481.87M | 557.87M | 478.94M |
| Operating Expenses | 1.06B | 1.33B | 1.36B | 1.36B | 1.97B |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| EBITDA | (317.41M) | (594.85M) | (453.69M) | 316.89M | (647.97M) |
| EBITDA Margin | -45.2% | -63.8% | -36.5% | 16.7% | -29.5% |
| Operating Income | (459.71M) | (536.2M) | (267.82M) | 218.08M | (657.77M) |
| Operating Margin | -65.5% | -57.5% | -21.5% | 11.5% | -29.9% |
| Interest Income | 511K | 27.72M | 85.97M | 71.77M | 19.57M |
| Interest Expense | 63.53M | 53.25M | 22.01M | 18.39M | 9.73M |
| Other Income / Expenses | 40.76M | (153.76M) | (252.27M) | 42.69M | (44.45M) |
| Income Before Tax | (418.95M) | (689.96M) | (520.1M) | 260.77M | (702.23M) |
| Pre-Tax Margin | -59.7% | -73.9% | -41.8% | 13.7% | -31.9% |
| Income Tax Expense | (168K) | 13.53M | 15.88M | 25.54M | 11.19M |
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Net Margin | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
| EPS (Basic) | (5.15) | (8.03) | (5.80) | 2.47 | (7.13) |
| EPS (Diluted) | (5.15) | (8.03) | (5.80) | 2.34 | (7.13) |
| Weighted Avg Shares | 81.26M | 87.56M | 92.4M | 95.08M | 104.79M |
| Weighted Avg Shares (Diluted) | 81.26M | 87.56M | 92.4M | 107.88M | 104.79M |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.